Patient characteristics
. | Cyclin D1-positive (n = 128) . | Cyclin D1-negative (n = 23) . | P . |
---|---|---|---|
Age (y), median (range) | 65 (36–81) | 60 (31–74) | .04 |
Age >60 | 81 (63%) | 11 (48%) | |
Sex (M/F) | 89/39 | 15/8 | .68 |
Stage | |||
I | 6 (5%) | 4 (17%) | |
II | 13 (10%) | 3 (13%) | .46 |
III | 32 (26%) | 3 (13%) | |
IV | 74 (59%) | 13 (56%) | |
Extranodal involvement | 87 (71%) | 17 (74%) | .80 |
≥2 sites | 43 (36%) | 8 (35%) | .88 |
BM and/or PB | 61 (50%) | 12 (52%) | .82 |
Spleen | 45 (36%) | 6 (26%) | .37 |
Liver | 19 (15%) | 4 (17%) | .80 |
GI tract | 34 (27%) | 2 (9%) | .05 |
Waldeyer ring | 13 (10%) | 2 (9%) | .59 |
Orbit | 3 (2%) | 3 (13%) | .05 |
Serum LDH > normal | 38 (33%) | 4 (18%) | .14 |
PS ≥2 | 24 (21%) | 2 (9%) | .16 |
International prognostic index | |||
Low | 28 (23%) | 9 (39%) | |
Low-intermediate | 39 (32%) | 9 (39%) | .04 |
High-intermediate | 31 (25%) | 4 (17%) | |
High | 19 (15%) | 1 (4%) |
. | Cyclin D1-positive (n = 128) . | Cyclin D1-negative (n = 23) . | P . |
---|---|---|---|
Age (y), median (range) | 65 (36–81) | 60 (31–74) | .04 |
Age >60 | 81 (63%) | 11 (48%) | |
Sex (M/F) | 89/39 | 15/8 | .68 |
Stage | |||
I | 6 (5%) | 4 (17%) | |
II | 13 (10%) | 3 (13%) | .46 |
III | 32 (26%) | 3 (13%) | |
IV | 74 (59%) | 13 (56%) | |
Extranodal involvement | 87 (71%) | 17 (74%) | .80 |
≥2 sites | 43 (36%) | 8 (35%) | .88 |
BM and/or PB | 61 (50%) | 12 (52%) | .82 |
Spleen | 45 (36%) | 6 (26%) | .37 |
Liver | 19 (15%) | 4 (17%) | .80 |
GI tract | 34 (27%) | 2 (9%) | .05 |
Waldeyer ring | 13 (10%) | 2 (9%) | .59 |
Orbit | 3 (2%) | 3 (13%) | .05 |
Serum LDH > normal | 38 (33%) | 4 (18%) | .14 |
PS ≥2 | 24 (21%) | 2 (9%) | .16 |
International prognostic index | |||
Low | 28 (23%) | 9 (39%) | |
Low-intermediate | 39 (32%) | 9 (39%) | .04 |
High-intermediate | 31 (25%) | 4 (17%) | |
High | 19 (15%) | 1 (4%) |
BM, bone marrow; PB, peripheral blood; GI, gastrointestinal; PS, performance status.